A new study published in the Journal of Clinical Oncology has found that vitamin D deficiency is linked to poor outcomes in patients with Hodgkin’s lymphoma, a form of cancer that originates in types of white blood cells known as lymphocytes. Examining data on 351 patients the researchers found that, prior to receiving treatment, half of them were deficient in vitamin D. In such patients, their progression-free survival – the length of time during and after treatment that they managed to live with the disease without their condition worsening – was significantly lower than those having sufficient levels of the nutrient. Vitamin D deficiency was also associated with reduced overall survival. The researchers concluded that vitamin D status is an independent predictor of outcome in Hodgkin’s lymphoma.
Interestingly, patients diagnosed during winter or spring were the most likely to be deficient in vitamin D. Conversely, those diagnosed during summer months were the most likely to have sufficient levels of the vitamin. The significance of these findings is supported by separate research showing that season of diagnosis is a strong prognostic factor in Hodgkin’s lymphoma. Patients diagnosed with the disease during winter have been shown to have a higher risk of fatality than those diagnosed during autumn.
The better outcomes of patients diagnosed with Hodgkin’s lymphoma during autumn are theorized to result from prior exposure to higher levels of sunshine. This is because UVB radiation from sun exposure has traditionally been the main contributor to levels of vitamin D in humans. When UVB from sunlight reaches the skin, vitamin D is produced naturally in the body. Higher levels of sun exposure during summer months may thus result in higher blood levels of vitamin D by autumn.
World Cancer Research Fund data shows a total of 589,580 cases of lymphoma were diagnosed worldwide during 2018. Around 13.5 percent of these were of the Hodgkin’s type, with the remainder being non-Hodgkin’s. Hodgkin’s lymphoma is distinguished by the presence of so-called ‘Reed-Sternberg’ cells. Such cells are not found in the non-Hodgkin’s form of the disease. In both forms, however, conventional approaches to treatment have failed to dramatically improve patient survival rates. Nor either have conventional approaches found any way of preventing lymphomas.
Examining alternative treatment options, scientists at the Dr. Rath Research Institute have tested a synergistic combination of nutrients against two of the most aggressive non-Hodgkin’s lymphoma cell lines. They found that a combination of vitamin C, the amino acids lysine and proline, green tea extract, and other nutrients was successful in stopping the secretion of specific enzymes that enable cancers to grow and spread. The nutrient combination was also able to induce apoptosis (cell death) in the tested cells by up to 100 percent. In another study the research team showed that the same nutrient combination could significantly reduce inflammatory markers, thereby reducing blood supply to tumors and decreasing their growth.
Given conventional medicine’s continued lack of safe and effective treatment options for lymphomas, there is an urgent need for alternative therapies to be explored and made available to patients. Based on the use of natural nutrients, the Cellular Medicine approach to lymphomas is completely safe and free from dangerous side-effects. Given the growing scientific evidence in favor of nutrient-based therapies for cancer, it is long since time that patients should have been given the option to be treated with them.